1. 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
2. E-2007
3. E2007
4. Er-155055-90
5. Fycompa
6. Perampanel Hydrate
7. Perampanel Hydrate (4:3)
1. 380917-97-5
2. Fycompa
3. E2007
4. Er-155055-90
5. E-2007
6. 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
7. E 2007
8. Perampanel (usan)
9. Chebi:71013
10. Benzonitrile, 2-(1',6'-dihydro-6'-oxo-1'-phenyl[2,3'-bipyridin]-5'-yl)-
11. 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
12. H821664npk
13. Perampanel [usan]
14. Fycompa (tn)
15. 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1'h)-one
16. 2-(6'-oxo-1'-phenyl-1',6'-dihydro-2,3'-bipyridin-5'-yl)benzonitrile
17. 2-(6'-oxo-1'-phenyl[1',6'-dihydro[2,3'-bipyridine]]-5'-yl)benzonitrile
18. Benzonitrile, 2-(1',6'-dihydro-6'-oxo-1'-phenyl(2,3'-bipyridin)-5'-yl)-
19. Perampanel [usan:inn]
20. Perampanelum
21. Unii-h821664npk
22. Perampanel(e2007
23. Perampanel [mi]
24. Perampanel [inn]
25. Perampanel [vandf]
26. Perampanel [who-dd]
27. Schembl194370
28. Gtpl7050
29. Chembl1214124
30. Perampanel [orange Book]
31. Dtxsid80191501
32. Bcp06505
33. Ex-a2128
34. Bdbm50184410
35. Zinc30691797
36. Akos016340421
37. Ch-0056
38. Cs-1160
39. Db08883
40. Sb16816
41. Ncgc00378863-02
42. Ac-27375
43. Am806751
44. Hy-14745
45. D08964
46. Q868658
47. 2-(6-oxo-1-phenyl-1,6-dihydro-[2,3-bipyridin]-5-yl)benzonitrile
48. 3-(2-cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one
49. 1174302-51-2
50. 6zp
| Molecular Weight | 349.4 g/mol |
|---|---|
| Molecular Formula | C23H15N3O |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 349.121512110 g/mol |
| Monoisotopic Mass | 349.121512110 g/mol |
| Topological Polar Surface Area | 57 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 664 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Fycompa |
| PubMed Health | Perampanel (By mouth) |
| Drug Classes | Anticonvulsant, Central Nervous System Agent |
| Drug Label | FYCOMPA tablets contain perampanel, a non-competitive AMPA receptor antagonist. Perampanel is described chemically as 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile hydrate (4:3).The molecular formula is C23H15N3O 3/4H2O,... |
| Active Ingredient | Perampanel |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 8mg; 4mg; 12mg; 6mg; 2mg; 10mg |
| Market Status | Prescription |
| Company | Eisai |
| 2 of 2 | |
|---|---|
| Drug Name | Fycompa |
| PubMed Health | Perampanel (By mouth) |
| Drug Classes | Anticonvulsant, Central Nervous System Agent |
| Drug Label | FYCOMPA tablets contain perampanel, a non-competitive AMPA receptor antagonist. Perampanel is described chemically as 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile hydrate (4:3).The molecular formula is C23H15N3O 3/4H2O,... |
| Active Ingredient | Perampanel |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 8mg; 4mg; 12mg; 6mg; 2mg; 10mg |
| Market Status | Prescription |
| Company | Eisai |
Used in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
FDA Label
Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.
Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
Perampanel is involved in inhibiting neuronal excitation in the central nervous system leading to such effects as decreased pyschomotor performance.
N03AX22
N03AX22
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX22 - Perampanel
Absorption
After oral adminitration, perampanel is absorbed rapidly and completely.
Route of Elimination
Perampanel is eliminated mostely in the feces (48%) and to a lesser exten in the urine (22%).
Volume of Distribution
The volume of distribution of perampanel was not quantified.
Clearance
In healthy patients, perampanel has a clearance of about 12 mL/min.
Perampanel is highly metabolized by CYP3A4 and/or CYP3A5 primary oxidation and by sequential glucuronidation.
Perampanel has a long elmination half-life of about 105 hours.
The exact mechanism of action of perampanel in seizures is not yet determined, but it is known that perampanel decreases neuronal excitation by non-competitive ihibition of the AMPA receptor.
LOOKING FOR A SUPPLIER?
